引導式測驗 · 中等 等級

人工智慧在藥物安全和藥物警戒測驗的應用

審查跨產品藥品安全監測工作流程中的不良事件報告、訊號檢測和標準化編碼。

問題 1 的 8

藥物警戒的主要目標是什麼?

預覽每個問題8 問題

當您參加測驗時,就會出現答案和解釋。

  1. 藥物警戒的主要目標是什麼?
    • 檢測、評估和預防藥物使用後的危害
    • 向醫師推銷新藥
    • 設定藥品零售價
    • 設計藥丸包裝
  2. In the published n2c2 clinical NLP system, what information did the system extract from narrative notes?
    • Only patients’ handwritten signatures
    • Medication and adverse-event concepts and their relations
    • Only final regulatory decisions
    • Only medicine prices
  3. 不成比例分析在不良事件資料庫中偵測到什麼?
    • 品牌藥和仿製藥之間的價格差異
    • 哪家醫院提交的報告最多
    • 藥物事件對的報告頻率比統計機率預測的要高
    • 藥物的有效期限
  4. What is VigiBase, according to Uppsala Monitoring Centre?
    • A database of randomized clinical-trial efficacy results only
    • A list of confirmed causal side effects for every medicine
    • A commercial catalogue of approved drug prices
    • The WHO global database of reported adverse events for medicines and vaccines
  5. MedDRA 在藥物警戒管道中的用途是什麼?
    • 用於編碼反應和狀況的標準化醫學詞彙
    • 某醫藥包裝品牌
    • 專為醫生設計的日程安排應用程序
    • 一種 MRI 掃描儀
  6. Which sequence does UMC describe in its signal-management process?
    • Diagnosis, prescription, dispensing, billing and discharge
    • Detection, validation, prioritisation, assessment and communication
    • Data collection, automatic causality decision, recall and litigation
    • Model training, deployment, billing and marketing
  7. How should a high disproportionality score in a spontaneous-report database be interpreted?
    • As a population incidence rate for all patients
    • As a confirmed causal adverse reaction
    • As a statistical signal for further assessment, not proof that the drug caused the event
    • As proof that no other factor contributed
  8. Which four elements satisfy the minimum ICSR criteria in ICH E2D(R1)?
    • A confirmed causal link, a batch number, a prescriber signature, and a laboratory result
    • A product label, a randomized trial, a treatment response, and a safety committee vote
    • A hospital admission, a known dose, a genetic profile, and a published case report
    • An adverse event or other observation, a suspect or interacting product, an identifiable patient, and an identifiable reporter